NuclearMediX is a healthcare biotechnology company developing radiopharmaceutical solutions for cancer diagnostics, with a focus on SSTR-PET tracers used to diagnose neuroendocrine tumours and other cancers. Its work centres on an innovative 18F radiotracer platform designed to improve the availability, affordability and reliability of PET imaging agents. The company’s flagship product, [18F]FET-βAG-TOCA, aims to address shortages, production limits and short shelf-life issues affecting existing diagnostic tracers. Serving oncologists and nuclear medicine departments, NuclearMediX operates within the radiopharmaceuticals, molecular imaging and cancer care sectors.
This is a company profile stub. Create an account to claim your profile.
Industry
BiotechnologyAreas of Focus
Location
Hounslow
Status
Active
